The Biostat Research and Development Center has signed an agreement with Corza Medical to conduct a PASS study in the area of surgery.

The PASS study (Post Authorization Safety Study) will concern the use of human Fibrinogen and human Thrombin in paediatric patients during surgical procedures.

- We will be responsible for the comprehensive management of the study, i.e. obtaining the consent of regulatory bodies to conduct the study, contracting centers, eCRF, statistics, monitoring and project management

– enumerates Edyta Klemba - Pharma Division Director at Biostat.

Corza Medical is a leading global manufacturer of innovative surgical technologies and solutions, enabling customers and partners to deliver exceptional surgical care, improving patient outcomes worldwide.  Learn more at https://corza.com/